AI Drug Discovery for Pharma and Biotech

Drug discovery

43

papers

On emerging therapies

Overview

Coffin-Siris syndrome (CSS) is a rare genetic disorder caused by pathogenic variants in BAF chromatin-remodeling complex genes (ARID1B, SMARCA4, and others), characterized by developmental delay, intellectual disability, fifth-digit hypoplasia/aplasia, coarse facial features, and multi-system involvement (cardiac, ophthalmologic, neurologic). Diagnosis relies on clinical findings and molecular testing [1][12][17].

Population

~200-250 reported cases with female predominance; most cases arise from de novo mutations (ARID1B-linked in 35-40%) [1][5][7].

Burden

Lifelong disability requiring intensive care coordination, high rates of comorbidities (60% feeding issues, 50% seizures), and increased mortality risks from aspiration pneumonia or refractory epilepsy. Tumor predisposition (e.g., hepatoblastoma) warrants surveillance [1][4][14].

Therapies

Supportive care (occupational/speech/physical therapy), surgical correction of anomalies (cardiac, craniofacial), seizure management, and multidisciplinary monitoring (growth, vision, hearing). Emerging evidence supports immunosuppressants for inflammatory arthritis [4][11][17].

Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare neurological diseases

Research Papers

43 drug discovery papers about Coffin-Siris syndrome. Recent publications:

43 drug discovery papers about Coffin-Siris syndrome. Recent publications:

categories:

Small molecules

gene therapies
2026-05-31 | Same Gene, Different Journeys : Four Faces of Coffin-Siris Syndrome

Background: Coffin–Siris syndrome (CSS) is a rare neurodevelopmentaldisorder caused by pathogenic variants in genes of the BAF chromatinremodellingcomplex, most commonly ARID1B. It is characterized bydevelopmental delay, dysmorphic features, seizures, feeding difficulties,and variable fifth-digit anomalies. Marked phenotypic heterogeneity oftenleads to delayed recognition, particularly in resource-limited settings.Methods: We report a case series of four genetically confirmed children with6q25.3–q27 deletions involving ARID1B, evaluated at a tertiary care centre. Clinical,neurological, radiological, audiological, and molecular findings were analyzed.Results: All four children presented in infancy with global developmental delay,recurrent seizures, and significant feeding difficulties requiring nutritionalsupport. Dysmorphic facial features were present in all cases; however, classicalfifth-digit hypoplasia was observed in only one child. Neuroimaging revealedstructural brain abnormalities in all patients, including corpus callosumthinning, cerebellar vermis hypoplasia, hydrocephalus, and periventricularleukomalacia. Electroencephalography showed generalized backgroundslowing in each case. Hearing impairment was identified in three children.Muscle tone varied, with hypotonia in three cases and hypertonia in one,highlighting phenotypic diversity despite a shared molecular basis. Wholeexomesequencing confirmed de novo deletions involving ARID1B in all patients.Conclusion: This case series underscores the broad clinical spectrum ofARID1B-related CSS and demonstrates significant genotype–phenotypevariability even among patients with similar chromosomal deletions. Limbanomalies may be absent, and neurological manifestations predominate.Early genetic evaluation in infants with unexplained developmental delayand dysmorphism facilitates timely diagnosis, multidisciplinary management,and genetic counselling. Increased awareness and integration of moleculartesting are essential to improve recognition of CSS in developing countries.

Open article ↗



2026-01-28 | Beyond Neurodevelopmental Delay: BICRA-Related Coffin-Siris Syndrome 12 with Severe Intestinal Dysmotility and Recurrent Pneumothorax.

Coffin-Siris syndrome 12 (CSS12) is a recently described neurodevelopmental disorder caused by heterozygous pathogenic variants in BICRA, a gene encoding a core subunit of the non-canonical BAF (ncBAF) chromatin-remodeling complex. The condition is characterized by developmental delay, hypotonia, hypertrichosis, and joint laxity. However, long-term data remain limited, and systemic manifestations are incompletely defined. We report a 22-year-old male with a de novo BICRA frameshift variant, c.2479_2480delinsA (p.Ala827Thrfs*15), previously included in the original cohort reported by Barish et al. Longitudinal follow-up revealed an expanded phenotype extending beyond neurodevelopmental features. Early findings included global developmental delay, growth hormone deficiency, short stature, and joint hypermobility. In adolescence and adulthood, he developed severe intestinal dysmotility requiring total colectomy, recurrent spontaneous pneumothoraces from bilateral apical bullous disease, and portal-vein thrombosis, representing visceral and vascular complications not previously emphasized in BICRA-related disorders. The identified BICRA variant truncates the coiled-coil domain critical for BRD9/BRD4 interaction, consistent with a loss-of-function mechanism. The patient's systemic features suggest that BICRA haploinsufficiency affects not only neurodevelopmental pathways but also smooth-muscle and connective-tissue integrity. This case expands the phenotypic spectrum of BICRA-related CSS12, demonstrating that visceral and vascular involvement can occur alongside neurodevelopmental and connective-tissue features. Recognition of these broader manifestations underscores the need for lifelong multidisciplinary surveillance and contributes to understanding the diverse biological roles of the ncBAF complex in human development.

Open article ↗



2026-01-22 | Expanding the Phenotypic Spectrum Associated With Loss-of-Function SMARCA4 Variants to Eye Developmental Anomalies.

The SMARCA4 gene encodes a catalytic subunit of the BRG1/BRM-associated factor complex, which regulates gene expression through chromatin remodeling. Heterozygous missense variants in this gene have been linked to Coffin-Siris syndrome, characterized by intellectual development disorder and various congenital anomalies (distinctive facial features, hypoplastic fifth digits, and malformations of the heart and central nervous system), but it is not typically associated with structural eye anomalies. Truncating variants in SMARCA4 have been associated with rhabdoid tumors predisposition syndrome, a group of rare and aggressive tumors occurring predominantly in infancy. Through pangenomic analyses (whole-exome or whole-genome sequencing), we identified loss-of-function variants in SMARCA4 in three unrelated individuals with microphthalmia and/or coloboma. None of these individuals had a history of rhabdoid tumors; however, a regular oncological follow-up was established following the SMARCA4 variant identification. Systemic features observed in these individuals consisted of developmental delay and brain anomalies. However, their clinical presentation does not align with classic features of Coffin-Siris syndrome. Although eye development anomalies have occasionally been reported in individuals with a pathogenic variant in SMARCA4, no clear association has been established to date. The description of these three new individuals provides further evidence supporting the role of SMARCA4 in eye development and its likely involvement in structural eye malformations.

Open article ↗



2026-01-17 | Identification of novel variants in the ARID1B gene causing Coffin-Siris syndrome.

Coffin-Siris Syndrome (CSS) is a neurodevelopmental disorder caused by variants in genes encoding BRG1- and BRM-associated factor (BAF) chromatin-remodeling complex. ARID1B gene variants are the most common cause of CSS. This study aimed to identify novel pathogenic ARID1B variants in patients clinically diagnosed with CSS and to explore their pathogenic role. In this study, eight patients clinically diagnosed with CSS were enrolled, and whole exome sequencing (WES) was performed to identify potential pathogenic variants. Heterozygous variants in the ARID1B gene were identified in six patients, including one previously reported pathogenic nonsense variant and five novel pathogenic truncating variants. The combined annotation-dependent depletion (CADD) scores of the five novel variants were significantly above the mutation significance cutoff (MSC), suggesting their potential pathogenicity. According to the guidelines of the American College of Medical Genetics and Genomics (ACMG), these five novel variants were classified as pathogenic. Our findings add five novel variants to the list of known pathogenic variants of the ARID1B gene. This study further clarifies an enhanced connection between ARID1B gene variants and CSS and expands the variant spectrum of CSS. • Coffin-Siris syndrome (CSS) is a rare neurodevelopmental disorder characterized by developmental delay, intellectual disability, and hypoplasia of the fifth digits or nails. • Pathogenic variants in genes encoding subunits of the BAF chromatin-remodeling complex are the major genetic causes of CSS, with ARID1B being the most frequently mutated gene, and most variants of which are truncating and lead to haploinsuffucuency. • Five novel heterozygous truncating variants in ARID1B were identified in eight patients clinically diagnosed with Coffin-Siris syndrome. • All novel variants showed high CADD scores and were classified as pathogenic according to ACMG guidelines.

Open article ↗



2025-11-27 | Prenatal Diagnosis of 6q Terminal Deletion Associated with Coffin-Siris Syndrome: Phenotypic Delineation and Review.

Chromosome 6q deletion syndrome is a rare entity that has a highly variable clinical presentation and size of deletions. The most frequent manifestations of 6q terminal deletion are intellectual disability, facial dysmorphism, brain structural anomalies, and congenital heart defects. The phenotype is not clinically recognizable, except in those who harbor a terminal 6q deletion that includes the ARID1B gene, in whom features similar to Coffin-Siris syndrome (CSS) can be observed. We report the case of a female newborn with a prenatal diagnosis of a terminal deletion on 6q25.1q27, which encompasses the ARID1B gene, and who was diagnosed with CSS during the neonatal period. From our review, we found that facial gestalt, hypertrichosis, and fifth fingernail aplasia/hypoplasia, along with other features, such as vertebral defects and cystic hygroma (or webbed neck), correlated with the presence of a CSS causally related to 6q25.3 small deletions that include the ARID1B gene.

Open article ↗



proteins
2026-07-09 | Table 5_Impaired IFN-γ-mediated innate and adaptive immunity in Coffin-Siris syndrome type 2: immunological insights from a patient with a recurrent ARID1A mutation.xlsx

Background Coffin-Siris syndrome type 2 (CSS2), caused by ARID1A mutations, is characterized by neurodevelopmental delay and recurrent infections. The ARID1A p.Ala1077Glu variant has been linked to CSS2, but the immune mechanisms underlying infection susceptibility remain poorly understood. Methods The variant was identified by trio-based whole-exome sequencing and confirmed by Sanger sequencing. Immune status was assessed via serum immunoglobulins, complement measurements, and flow cytometric immunophenotyping. RNA sequencing was performed on PMA-stimulated PBMCs from the patient and healthy controls, with key findings validated by qRT-PCR and ELISA. Results Immune profiling revealed widespread quantitative deficits across innate and adaptive compartments, with particularly marked reductions in NKT-like cells (CD3+CD56+) and CD8+ central memory T cells. Transcriptomic analysis of stimulated cells uncovered a profound activation defect, characterized by widespread downregulation of effector immune genes. Furthermore, pathway enrichment analysis demonstrated significant suppression of multiple biological processes critically dependent on IFN-γ signaling, such as antigen processing and presentation, and Th1/Th17 cell differentiation. Expression of IFNG, STAT1, and CXCL9 showed a trend toward decreased expression. Conclusion Our findings suggest an association between the ARID1A p.Ala1077Glu variant and impaired IFN-γ-mediated immunity in CSS2, potentially contributing to recurrent infections. The IFN-γ pathway warrants further investigation as a therapeutic target.

Open article ↗



2026-07-09 | Impaired IFN-γ-mediated innate and adaptive immunity in Coffin-Siris syndrome type 2: immunological insights from a patient with a recurrent ARID1A mutation

Background Coffin-Siris syndrome type 2 (CSS2), caused by ARID1A mutations, is characterized by neurodevelopmental delay and recurrent infections. The ARID1A p.Ala1077Glu variant has been linked to CSS2, but the immune mechanisms underlying infection susceptibility remain poorly understood. Methods The variant was identified by trio-based whole-exome sequencing and confirmed by Sanger sequencing. Immune status was assessed via serum immunoglobulins, complement measurements, and flow cytometric immunophenotyping. RNA sequencing was performed on PMA-stimulated PBMCs from the patient and healthy controls, with key findings validated by qRT-PCR and ELISA. Results Immune profiling revealed widespread quantitative deficits across innate and adaptive compartments, with particularly marked reductions in NKT-like cells (CD3 + CD56 + ) and CD8 + central memory T cells. Transcriptomic analysis of stimulated cells uncovered a profound activation defect, characterized by widespread downregulation of effector immune genes. Furthermore, pathway enrichment analysis demonstrated significant suppression of multiple biological processes critically dependent on IFN-γ signaling, such as antigen processing and presentation, and Th1/Th17 cell differentiation. Expression of IFNG , STAT1 , and CXCL9 showed a trend toward decreased expression. Conclusion Our findings suggest an association between the ARID1A p.Ala1077Glu variant and impaired IFN-γ-mediated immunity in CSS2, potentially contributing to recurrent infections. The IFN-γ pathway warrants further investigation as a therapeutic target.

Open article ↗



2026-04-13 | ARID1B regulates sphingolipid metabolism and myelin development via STAG2: Mechanistic insights into ARID1B-related coffin-siris syndrome.

Coffin-Siris syndrome (CSS) is predominantly attributed to variants in ARID1B gene, however, the molecular pathways connecting ARID1B to myelination and neural development are not well elucidated. We employed ARID1B knockdown in SK-N-SH cells coupled with transcriptomic analysis to identify downstream targets. We conducted quantitative Real-Time PCR, Western blotting, chromatin immunoprecipitation (ChIP) and co-immunoprecipitation (Co-IP) assays to investigate the regulatory mechanisms of ARID1B. The clinical phenotypes of three CSS patients with pathogenic ARID1B variants were examined to evaluate myelination defects. ARID1B knockdown resulted in a significantly reduction in expression of STAG2 and key genes involved in sphingolipid metabolism (SPTLC1, ACER3, CERS5), which was rescued by exogenous STAG2 overexpression. ChIP assays demonstrated direct binding of ARID1B to the STAG2 promoter, confirming its role in transcriptional regulation. ARID1B deficiency also led to the downregulation of the myelin gene PLP1 and the upregulation of the synaptic gene ARC, both of which were rescued upon STAG2 restoration. Clinically, all three CSS patients exhibited characteristics indicative of hypomyelination, including motor delay and delayed myelination. Our study reveals a novel ARID1B-STAG2-sphingolipid metabolic axis that is essential for myelin formation and neural function. These findings enhance the understanding of CSS pathogenesis and suggest potential molecular targets for therapeutic intervention in ARID1B-related neurodevelopmental disorders.

Open article ↗



2024-09-16 | More than three years' treatment response of recombinant human growth hormone in a patient with Coffin-Siris syndrome 7.

Not required for Clinical Vignette.

Open article ↗



2022-08-13 | Short stature and melanocytic nevi in a girl with ARID1B-related Coffin-Siris syndrome: a case report

Coffin-Siris syndrome (CSS) is a rare autosomal dominant disorder characterized by intellectual disability, developmental delay, and characteristic facial features. Few patients with cutaneous phenotype in this rare syndrome have been reported.Herein, we describe a 12-year-old Chinese girl diagnosed with CSS, who was referred to our hospital because of intellectual disability and short stature. Prominent characteristics of the cutaneous system were observed: (1) A congenital giant nevus from the left frontal and temporal regions to the entire left scalp; and (2) multiple melanocytic nevi on the face and trunk. Whole exome sequencing revealed a novel heterozygous variant in the ARID1B gene. Recombinant human growth hormone (rhGH) was given for short stature, and resulted in significantly improved height. No enlargement or malignant transformation of nevi occurred within 4 years of follow-up.The symptoms in cutaneous system is noteworthy,which may be a neglected phenotype in CSS.The therapeutic response of growth hormone is effective in this patient and no tumor related signs were found.

Open article ↗



small molecules
2026-05-07 | [Clinical characteristics and genetic analysis of a child with Coffin-Siris syndrome type 8 due to an intronic variant of SMARCC2 gene].

To explore the clinical phenotype and genetic characteristics of a child with Coffin-Siris syndrome type 8 (CSS8) due to an intronic variant of the SMARCC2 gene. A child who had attended the Women and Children's Hospital of Ningbo University on 5 March, 2025 was selected as study subject. Clinical data of the child was collected. Peripheral blood samples were collected from the child and her family members. Following extraction of genomic DNA, whole exome sequencing (WES) was carried out. Candidate variants was validated by Sanger sequencing. The effect of candidate variants on mRNA was analyzed using an in vitro minigene assay. CSS8-related publications were searched in home and oversea databases for a literature review. This study was approved by the Medical Ethics Committee of the hospital (Ethics No.: EC2023-094). The child had manifested intellectual disability, delayed language development, recurrent fever, rash, joint pain, and chronic multifocal aseptic osteomyelitis. WES revealed that she has harbored a heterozygous c.1496+2T>C variant of the SMARCC2 gene, which may affect the splicing of mRNA. Sanger sequencing verified that neither of her parents has carried the same variant. In vitro minigene assay indicated that the variant can affect the normal splicing of SMARCC2 mRNA and result in two abnormal transcripts including retaining of 126 bp upstream of intron 16 and skipping of exon 16. Both splicing forms did not alter the reading frame, but resulted in production of truncated proteins. Based on the guidelines from American College of Medical Genetics and Genomics (ACMG), the variant was rated as likely pathogenic (PS2_Moderate+PVS1_Moderate+PM2_Supporting+PS1_Supporting). The child was treated with naproxen and adalimumab, though she still had repeated episodes of attacks. After hormone supplementation and methotrexate treatment, her condition was relieved. The c.1496+2T>C variant of the SMARCC2 gene probably underlay the pathogenesis of CSS8 in this child. Above finding has enriched the mutational and phenotypic spectra of the SMARCC2 gene.

Open article ↗



2024-11-20 | A novel mutation in SMARCB1 associated with adult Coffin-Siris syndrome and meningioma.

SMARCB1 encodes a core subunit of the SWI/SNF chromatin remodeling complex, which plays a crucial role in the regulation of gene expression. Germline mutations in the SMARCB1 gene have been linked to early childhood Coffin-Siris syndrome type 3 (CSS3), a rare congenital malformation syndrome characterized by severe developmental delay and intellectual disability. In this study, we report a family of two adult CSS3 patients with a novel missense SMARCB1 mutation (c.1091A>C, p.Lys364Thr) identified through whole-exome sequencing (WES). Both patients exhibit selective difficulties in verbal learning and experience language delays. Additionally, the development of meningioma is confirmed in one of the patients. Mechanistic studies suggest that this missense mutation may abnormally activate the MAPK signaling pathway, which is implicated in the pathogenesis of tumor progression and neurodevelopmental disorders. This is the first reported case of a germline mutation in the SMARCB1 gene associated with both CSS3 and meningioma, thereby expanding the phenotypic spectrum of SMARCB1-related disorders.

Open article ↗



2023-09-01 | #36280 Neuraxial anaesthesia in a patient with coffin-siris syndrome – a case report



Please confirm that an ethics committee approval has been applied for or granted: Not relevant (see information at the bottom of this page)

Background and Aims

Coffin-Siris syndrome (CSS) is a rare genetic disorder, with less than 250 molecularly confirmed cases worldwide. It is characterized by growth restriction, developmental delay, craniofacial malformations, and a range of heart, gastrointestinal, genitourinary and nervous system abnormalities. These abnormalities may present an anaesthetic challenge mainly due to difficult airway management, respiratory complications and poor patient cooperation. The available literature on CSS anaesthetic approach consists of 10 case reports, with only one describing a regional anaesthesia technique.

Methods

A 14-year-old female patient with CSS was scheduled for bilateral proximal tibial hemiepiphysiodesis. Preoperative evaluation was significant for developmental delay, obstructive sleep apnoea, IgA deficiency with several respiratory infections over the last year and hypertrophic cardiomyopathy. A history of doubtful delayed emergence from general anaesthesia, despite recovery of spontaneous ventilation, was present in past procedures. Physical examination revealed obesity, a short neck and macroglossia. A deep sedation was accomplished intravenously with propofol and fentanyl, and maintained with sevoflurane 1,5%, ensuring spontaneous ventilation through a laryngeal mask airway. An L3-L4 epidural block was performed with ropivacaine 0,5%. ASA standard monitoring and bispectral index were applied, and multimodal analgesia was ensured.

Results

Hemiepiphysiodesis was successfully performed under the proposed anaesthetic technique, combining neuraxial anaesthesia and sedation. The perioperative period was uneventful.

Conclusions

CSS patients can be challenging for the anaesthesiologist due to the syndrome’s malformation spectrum, cardiac structural disease, respiratory complications and lack of reassuring literature. Neuraxial anaesthesia may be a successful and safe approach for CSS patients in selected procedures.


Open article ↗



2022-12-19 | Acetate supplementation restores cognitive deficits caused by ARID1A haploinsufficiency in excitatory neurons.

Mutations in AT-rich interactive domain-containing protein 1A (ARID1A) cause Coffin-Siris syndrome (CSS), a rare genetic disorder that results in mild to severe intellectual disabilities. However, the biological role of ARID1A in the brain remains unclear. In this study, we report that the haploinsufficiency of ARID1A in excitatory neurons causes cognitive impairment and defects in hippocampal synaptic transmission and dendritic morphology in mice. Similarly, human embryonic stem cell-derived excitatory neurons with deleted ARID1A exhibit fewer dendritic branches and spines, and abnormal electrophysiological activity. Importantly, supplementation of acetate, an epigenetic metabolite, can ameliorate the morphological and electrophysiological deficits observed in mice with Arid1a haploinsufficiency, as well as in ARID1A-null human excitatory neurons. Mechanistically, transcriptomic and ChIP-seq analyses demonstrate that acetate supplementation can increase the levels of H3K27 acetylation at the promoters of key regulatory genes associated with neural development and synaptic transmission. Collectively, these findings support the essential roles of ARID1A in the excitatory neurons and cognition and suggest that acetate supplementation could be a potential therapeutic intervention for CSS.

Open article ↗



2021-05-19 | A partial ARID1B deletion in a female child with intractable epilepsy

Although epilepsy is a known complication in Coffin-Siris syndrome, its clinical symptoms and effective treatment methods have not been thoroughly investigated so far. Here, we present the case of a female with a 594-kb interstitial deletion at 6q25.3, involving partially ARID1B, with developmental delay, short stature, and intractable epilepsy. At 4 years of age, she developed epilepsy with clonic seizures in the right half of her body. Treatment with carbamazepine, levetiracetam, or topiramate was ineffective. The frequency of epileptic seizures gradually worsened. At the peak of her seizures, she had focal onset clonic seizures 3-4 times a month, and neck atonic seizures lasting for several seconds more than 10 times a day. After administration of sodium valproate, her epileptic seizures decreased to 0-1 times a year. In conclusion, gathering genetic information in Coffin-Siris syndrome allows improvement of epilepsy treatment and outcomes in these patients.

Open article ↗



cell therapies
2026-04-09 | Intranasal exosome therapy in Coffin-Siris syndrome: Clinical evaluation of three children.

Coffin-Siris Syndrome (CSS) is a rare neurodevelopmental condition most often caused by pathogenic variants in the ARID1B gene, a key component of the SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin-remodeling complex. Despite multidisciplinary interventions, functional improvement in CSS remains limited. Exosome-based therapeutics have recently gained attention for their potential neuroregenerative and neuroprotective properties. This case series included three children with genetically confirmed ARID1B-related CSS who received intranasal exosome therapy in addition to ongoing rehabilitation. Adaptive functioning was evaluated before and after treatment using the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3). Post-treatment assessments were performed 4-6 weeks after completion of the final intranasal exosome treatment cycle. Following the therapies, all patients demonstrated increases in the Adaptive Behavior Composite (ABC) score. The mean score increased from 83.0 pre-treatment to 90.7 post-treatment, corresponding to a mean improvement of 7.7 points (approximately +9%). Improvements were observed primarily in communication, daily living, and socialization domains, while motor-related changes were more modest yet clinically observable. No adverse events were observed during treatment. Given the small sample size, retrospective design, and concurrent rehabilitation therapies, these findings should be interpreted cautiously. These preliminary observations suggest that intranasal exosome therapy may represent a feasible and well-tolerated adjunctive approach to support adaptive functioning in children with CSS. Further controlled studies are warranted to confirm efficacy and elucidate the underlying mechanisms.

Open article ↗



gene therapies
2026-05-31 | Same Gene, Different Journeys : Four Faces of Coffin-Siris Syndrome

Background: Coffin–Siris syndrome (CSS) is a rare neurodevelopmentaldisorder caused by pathogenic variants in genes of the BAF chromatinremodellingcomplex, most commonly ARID1B. It is characterized bydevelopmental delay, dysmorphic features, seizures, feeding difficulties,and variable fifth-digit anomalies. Marked phenotypic heterogeneity oftenleads to delayed recognition, particularly in resource-limited settings.Methods: We report a case series of four genetically confirmed children with6q25.3–q27 deletions involving ARID1B, evaluated at a tertiary care centre. Clinical,neurological, radiological, audiological, and molecular findings were analyzed.Results: All four children presented in infancy with global developmental delay,recurrent seizures, and significant feeding difficulties requiring nutritionalsupport. Dysmorphic facial features were present in all cases; however, classicalfifth-digit hypoplasia was observed in only one child. Neuroimaging revealedstructural brain abnormalities in all patients, including corpus callosumthinning, cerebellar vermis hypoplasia, hydrocephalus, and periventricularleukomalacia. Electroencephalography showed generalized backgroundslowing in each case. Hearing impairment was identified in three children.Muscle tone varied, with hypotonia in three cases and hypertonia in one,highlighting phenotypic diversity despite a shared molecular basis. Wholeexomesequencing confirmed de novo deletions involving ARID1B in all patients.Conclusion: This case series underscores the broad clinical spectrum ofARID1B-related CSS and demonstrates significant genotype–phenotypevariability even among patients with similar chromosomal deletions. Limbanomalies may be absent, and neurological manifestations predominate.Early genetic evaluation in infants with unexplained developmental delayand dysmorphism facilitates timely diagnosis, multidisciplinary management,and genetic counselling. Increased awareness and integration of moleculartesting are essential to improve recognition of CSS in developing countries.

Open article ↗



2026-01-28 | Beyond Neurodevelopmental Delay: BICRA-Related Coffin-Siris Syndrome 12 with Severe Intestinal Dysmotility and Recurrent Pneumothorax.

Coffin-Siris syndrome 12 (CSS12) is a recently described neurodevelopmental disorder caused by heterozygous pathogenic variants in BICRA, a gene encoding a core subunit of the non-canonical BAF (ncBAF) chromatin-remodeling complex. The condition is characterized by developmental delay, hypotonia, hypertrichosis, and joint laxity. However, long-term data remain limited, and systemic manifestations are incompletely defined. We report a 22-year-old male with a de novo BICRA frameshift variant, c.2479_2480delinsA (p.Ala827Thrfs*15), previously included in the original cohort reported by Barish et al. Longitudinal follow-up revealed an expanded phenotype extending beyond neurodevelopmental features. Early findings included global developmental delay, growth hormone deficiency, short stature, and joint hypermobility. In adolescence and adulthood, he developed severe intestinal dysmotility requiring total colectomy, recurrent spontaneous pneumothoraces from bilateral apical bullous disease, and portal-vein thrombosis, representing visceral and vascular complications not previously emphasized in BICRA-related disorders. The identified BICRA variant truncates the coiled-coil domain critical for BRD9/BRD4 interaction, consistent with a loss-of-function mechanism. The patient's systemic features suggest that BICRA haploinsufficiency affects not only neurodevelopmental pathways but also smooth-muscle and connective-tissue integrity. This case expands the phenotypic spectrum of BICRA-related CSS12, demonstrating that visceral and vascular involvement can occur alongside neurodevelopmental and connective-tissue features. Recognition of these broader manifestations underscores the need for lifelong multidisciplinary surveillance and contributes to understanding the diverse biological roles of the ncBAF complex in human development.

Open article ↗



2026-01-22 | Expanding the Phenotypic Spectrum Associated With Loss-of-Function SMARCA4 Variants to Eye Developmental Anomalies.

The SMARCA4 gene encodes a catalytic subunit of the BRG1/BRM-associated factor complex, which regulates gene expression through chromatin remodeling. Heterozygous missense variants in this gene have been linked to Coffin-Siris syndrome, characterized by intellectual development disorder and various congenital anomalies (distinctive facial features, hypoplastic fifth digits, and malformations of the heart and central nervous system), but it is not typically associated with structural eye anomalies. Truncating variants in SMARCA4 have been associated with rhabdoid tumors predisposition syndrome, a group of rare and aggressive tumors occurring predominantly in infancy. Through pangenomic analyses (whole-exome or whole-genome sequencing), we identified loss-of-function variants in SMARCA4 in three unrelated individuals with microphthalmia and/or coloboma. None of these individuals had a history of rhabdoid tumors; however, a regular oncological follow-up was established following the SMARCA4 variant identification. Systemic features observed in these individuals consisted of developmental delay and brain anomalies. However, their clinical presentation does not align with classic features of Coffin-Siris syndrome. Although eye development anomalies have occasionally been reported in individuals with a pathogenic variant in SMARCA4, no clear association has been established to date. The description of these three new individuals provides further evidence supporting the role of SMARCA4 in eye development and its likely involvement in structural eye malformations.

Open article ↗



2026-01-17 | Identification of novel variants in the ARID1B gene causing Coffin-Siris syndrome.

Coffin-Siris Syndrome (CSS) is a neurodevelopmental disorder caused by variants in genes encoding BRG1- and BRM-associated factor (BAF) chromatin-remodeling complex. ARID1B gene variants are the most common cause of CSS. This study aimed to identify novel pathogenic ARID1B variants in patients clinically diagnosed with CSS and to explore their pathogenic role. In this study, eight patients clinically diagnosed with CSS were enrolled, and whole exome sequencing (WES) was performed to identify potential pathogenic variants. Heterozygous variants in the ARID1B gene were identified in six patients, including one previously reported pathogenic nonsense variant and five novel pathogenic truncating variants. The combined annotation-dependent depletion (CADD) scores of the five novel variants were significantly above the mutation significance cutoff (MSC), suggesting their potential pathogenicity. According to the guidelines of the American College of Medical Genetics and Genomics (ACMG), these five novel variants were classified as pathogenic. Our findings add five novel variants to the list of known pathogenic variants of the ARID1B gene. This study further clarifies an enhanced connection between ARID1B gene variants and CSS and expands the variant spectrum of CSS. • Coffin-Siris syndrome (CSS) is a rare neurodevelopmental disorder characterized by developmental delay, intellectual disability, and hypoplasia of the fifth digits or nails. • Pathogenic variants in genes encoding subunits of the BAF chromatin-remodeling complex are the major genetic causes of CSS, with ARID1B being the most frequently mutated gene, and most variants of which are truncating and lead to haploinsuffucuency. • Five novel heterozygous truncating variants in ARID1B were identified in eight patients clinically diagnosed with Coffin-Siris syndrome. • All novel variants showed high CADD scores and were classified as pathogenic according to ACMG guidelines.

Open article ↗



2025-11-27 | Prenatal Diagnosis of 6q Terminal Deletion Associated with Coffin-Siris Syndrome: Phenotypic Delineation and Review.

Chromosome 6q deletion syndrome is a rare entity that has a highly variable clinical presentation and size of deletions. The most frequent manifestations of 6q terminal deletion are intellectual disability, facial dysmorphism, brain structural anomalies, and congenital heart defects. The phenotype is not clinically recognizable, except in those who harbor a terminal 6q deletion that includes the ARID1B gene, in whom features similar to Coffin-Siris syndrome (CSS) can be observed. We report the case of a female newborn with a prenatal diagnosis of a terminal deletion on 6q25.1q27, which encompasses the ARID1B gene, and who was diagnosed with CSS during the neonatal period. From our review, we found that facial gestalt, hypertrichosis, and fifth fingernail aplasia/hypoplasia, along with other features, such as vertebral defects and cystic hygroma (or webbed neck), correlated with the presence of a CSS causally related to 6q25.3 small deletions that include the ARID1B gene.

Open article ↗



proteins
2026-07-09 | Table 5_Impaired IFN-γ-mediated innate and adaptive immunity in Coffin-Siris syndrome type 2: immunological insights from a patient with a recurrent ARID1A mutation.xlsx

Background Coffin-Siris syndrome type 2 (CSS2), caused by ARID1A mutations, is characterized by neurodevelopmental delay and recurrent infections. The ARID1A p.Ala1077Glu variant has been linked to CSS2, but the immune mechanisms underlying infection susceptibility remain poorly understood. Methods The variant was identified by trio-based whole-exome sequencing and confirmed by Sanger sequencing. Immune status was assessed via serum immunoglobulins, complement measurements, and flow cytometric immunophenotyping. RNA sequencing was performed on PMA-stimulated PBMCs from the patient and healthy controls, with key findings validated by qRT-PCR and ELISA. Results Immune profiling revealed widespread quantitative deficits across innate and adaptive compartments, with particularly marked reductions in NKT-like cells (CD3+CD56+) and CD8+ central memory T cells. Transcriptomic analysis of stimulated cells uncovered a profound activation defect, characterized by widespread downregulation of effector immune genes. Furthermore, pathway enrichment analysis demonstrated significant suppression of multiple biological processes critically dependent on IFN-γ signaling, such as antigen processing and presentation, and Th1/Th17 cell differentiation. Expression of IFNG, STAT1, and CXCL9 showed a trend toward decreased expression. Conclusion Our findings suggest an association between the ARID1A p.Ala1077Glu variant and impaired IFN-γ-mediated immunity in CSS2, potentially contributing to recurrent infections. The IFN-γ pathway warrants further investigation as a therapeutic target.

Open article ↗



2026-07-09 | Impaired IFN-γ-mediated innate and adaptive immunity in Coffin-Siris syndrome type 2: immunological insights from a patient with a recurrent ARID1A mutation

Background Coffin-Siris syndrome type 2 (CSS2), caused by ARID1A mutations, is characterized by neurodevelopmental delay and recurrent infections. The ARID1A p.Ala1077Glu variant has been linked to CSS2, but the immune mechanisms underlying infection susceptibility remain poorly understood. Methods The variant was identified by trio-based whole-exome sequencing and confirmed by Sanger sequencing. Immune status was assessed via serum immunoglobulins, complement measurements, and flow cytometric immunophenotyping. RNA sequencing was performed on PMA-stimulated PBMCs from the patient and healthy controls, with key findings validated by qRT-PCR and ELISA. Results Immune profiling revealed widespread quantitative deficits across innate and adaptive compartments, with particularly marked reductions in NKT-like cells (CD3 + CD56 + ) and CD8 + central memory T cells. Transcriptomic analysis of stimulated cells uncovered a profound activation defect, characterized by widespread downregulation of effector immune genes. Furthermore, pathway enrichment analysis demonstrated significant suppression of multiple biological processes critically dependent on IFN-γ signaling, such as antigen processing and presentation, and Th1/Th17 cell differentiation. Expression of IFNG , STAT1 , and CXCL9 showed a trend toward decreased expression. Conclusion Our findings suggest an association between the ARID1A p.Ala1077Glu variant and impaired IFN-γ-mediated immunity in CSS2, potentially contributing to recurrent infections. The IFN-γ pathway warrants further investigation as a therapeutic target.

Open article ↗



2026-04-13 | ARID1B regulates sphingolipid metabolism and myelin development via STAG2: Mechanistic insights into ARID1B-related coffin-siris syndrome.

Coffin-Siris syndrome (CSS) is predominantly attributed to variants in ARID1B gene, however, the molecular pathways connecting ARID1B to myelination and neural development are not well elucidated. We employed ARID1B knockdown in SK-N-SH cells coupled with transcriptomic analysis to identify downstream targets. We conducted quantitative Real-Time PCR, Western blotting, chromatin immunoprecipitation (ChIP) and co-immunoprecipitation (Co-IP) assays to investigate the regulatory mechanisms of ARID1B. The clinical phenotypes of three CSS patients with pathogenic ARID1B variants were examined to evaluate myelination defects. ARID1B knockdown resulted in a significantly reduction in expression of STAG2 and key genes involved in sphingolipid metabolism (SPTLC1, ACER3, CERS5), which was rescued by exogenous STAG2 overexpression. ChIP assays demonstrated direct binding of ARID1B to the STAG2 promoter, confirming its role in transcriptional regulation. ARID1B deficiency also led to the downregulation of the myelin gene PLP1 and the upregulation of the synaptic gene ARC, both of which were rescued upon STAG2 restoration. Clinically, all three CSS patients exhibited characteristics indicative of hypomyelination, including motor delay and delayed myelination. Our study reveals a novel ARID1B-STAG2-sphingolipid metabolic axis that is essential for myelin formation and neural function. These findings enhance the understanding of CSS pathogenesis and suggest potential molecular targets for therapeutic intervention in ARID1B-related neurodevelopmental disorders.

Open article ↗



2024-09-16 | More than three years' treatment response of recombinant human growth hormone in a patient with Coffin-Siris syndrome 7.

Not required for Clinical Vignette.

Open article ↗



2022-08-13 | Short stature and melanocytic nevi in a girl with ARID1B-related Coffin-Siris syndrome: a case report

Coffin-Siris syndrome (CSS) is a rare autosomal dominant disorder characterized by intellectual disability, developmental delay, and characteristic facial features. Few patients with cutaneous phenotype in this rare syndrome have been reported.Herein, we describe a 12-year-old Chinese girl diagnosed with CSS, who was referred to our hospital because of intellectual disability and short stature. Prominent characteristics of the cutaneous system were observed: (1) A congenital giant nevus from the left frontal and temporal regions to the entire left scalp; and (2) multiple melanocytic nevi on the face and trunk. Whole exome sequencing revealed a novel heterozygous variant in the ARID1B gene. Recombinant human growth hormone (rhGH) was given for short stature, and resulted in significantly improved height. No enlargement or malignant transformation of nevi occurred within 4 years of follow-up.The symptoms in cutaneous system is noteworthy,which may be a neglected phenotype in CSS.The therapeutic response of growth hormone is effective in this patient and no tumor related signs were found.

Open article ↗



small molecules
2026-05-07 | [Clinical characteristics and genetic analysis of a child with Coffin-Siris syndrome type 8 due to an intronic variant of SMARCC2 gene].

To explore the clinical phenotype and genetic characteristics of a child with Coffin-Siris syndrome type 8 (CSS8) due to an intronic variant of the SMARCC2 gene. A child who had attended the Women and Children's Hospital of Ningbo University on 5 March, 2025 was selected as study subject. Clinical data of the child was collected. Peripheral blood samples were collected from the child and her family members. Following extraction of genomic DNA, whole exome sequencing (WES) was carried out. Candidate variants was validated by Sanger sequencing. The effect of candidate variants on mRNA was analyzed using an in vitro minigene assay. CSS8-related publications were searched in home and oversea databases for a literature review. This study was approved by the Medical Ethics Committee of the hospital (Ethics No.: EC2023-094). The child had manifested intellectual disability, delayed language development, recurrent fever, rash, joint pain, and chronic multifocal aseptic osteomyelitis. WES revealed that she has harbored a heterozygous c.1496+2T>C variant of the SMARCC2 gene, which may affect the splicing of mRNA. Sanger sequencing verified that neither of her parents has carried the same variant. In vitro minigene assay indicated that the variant can affect the normal splicing of SMARCC2 mRNA and result in two abnormal transcripts including retaining of 126 bp upstream of intron 16 and skipping of exon 16. Both splicing forms did not alter the reading frame, but resulted in production of truncated proteins. Based on the guidelines from American College of Medical Genetics and Genomics (ACMG), the variant was rated as likely pathogenic (PS2_Moderate+PVS1_Moderate+PM2_Supporting+PS1_Supporting). The child was treated with naproxen and adalimumab, though she still had repeated episodes of attacks. After hormone supplementation and methotrexate treatment, her condition was relieved. The c.1496+2T>C variant of the SMARCC2 gene probably underlay the pathogenesis of CSS8 in this child. Above finding has enriched the mutational and phenotypic spectra of the SMARCC2 gene.

Open article ↗



2024-11-20 | A novel mutation in SMARCB1 associated with adult Coffin-Siris syndrome and meningioma.

SMARCB1 encodes a core subunit of the SWI/SNF chromatin remodeling complex, which plays a crucial role in the regulation of gene expression. Germline mutations in the SMARCB1 gene have been linked to early childhood Coffin-Siris syndrome type 3 (CSS3), a rare congenital malformation syndrome characterized by severe developmental delay and intellectual disability. In this study, we report a family of two adult CSS3 patients with a novel missense SMARCB1 mutation (c.1091A>C, p.Lys364Thr) identified through whole-exome sequencing (WES). Both patients exhibit selective difficulties in verbal learning and experience language delays. Additionally, the development of meningioma is confirmed in one of the patients. Mechanistic studies suggest that this missense mutation may abnormally activate the MAPK signaling pathway, which is implicated in the pathogenesis of tumor progression and neurodevelopmental disorders. This is the first reported case of a germline mutation in the SMARCB1 gene associated with both CSS3 and meningioma, thereby expanding the phenotypic spectrum of SMARCB1-related disorders.

Open article ↗



2023-09-01 | #36280 Neuraxial anaesthesia in a patient with coffin-siris syndrome – a case report



Please confirm that an ethics committee approval has been applied for or granted: Not relevant (see information at the bottom of this page)

Background and Aims

Coffin-Siris syndrome (CSS) is a rare genetic disorder, with less than 250 molecularly confirmed cases worldwide. It is characterized by growth restriction, developmental delay, craniofacial malformations, and a range of heart, gastrointestinal, genitourinary and nervous system abnormalities. These abnormalities may present an anaesthetic challenge mainly due to difficult airway management, respiratory complications and poor patient cooperation. The available literature on CSS anaesthetic approach consists of 10 case reports, with only one describing a regional anaesthesia technique.

Methods

A 14-year-old female patient with CSS was scheduled for bilateral proximal tibial hemiepiphysiodesis. Preoperative evaluation was significant for developmental delay, obstructive sleep apnoea, IgA deficiency with several respiratory infections over the last year and hypertrophic cardiomyopathy. A history of doubtful delayed emergence from general anaesthesia, despite recovery of spontaneous ventilation, was present in past procedures. Physical examination revealed obesity, a short neck and macroglossia. A deep sedation was accomplished intravenously with propofol and fentanyl, and maintained with sevoflurane 1,5%, ensuring spontaneous ventilation through a laryngeal mask airway. An L3-L4 epidural block was performed with ropivacaine 0,5%. ASA standard monitoring and bispectral index were applied, and multimodal analgesia was ensured.

Results

Hemiepiphysiodesis was successfully performed under the proposed anaesthetic technique, combining neuraxial anaesthesia and sedation. The perioperative period was uneventful.

Conclusions

CSS patients can be challenging for the anaesthesiologist due to the syndrome’s malformation spectrum, cardiac structural disease, respiratory complications and lack of reassuring literature. Neuraxial anaesthesia may be a successful and safe approach for CSS patients in selected procedures.


Open article ↗



2022-12-19 | Acetate supplementation restores cognitive deficits caused by ARID1A haploinsufficiency in excitatory neurons.

Mutations in AT-rich interactive domain-containing protein 1A (ARID1A) cause Coffin-Siris syndrome (CSS), a rare genetic disorder that results in mild to severe intellectual disabilities. However, the biological role of ARID1A in the brain remains unclear. In this study, we report that the haploinsufficiency of ARID1A in excitatory neurons causes cognitive impairment and defects in hippocampal synaptic transmission and dendritic morphology in mice. Similarly, human embryonic stem cell-derived excitatory neurons with deleted ARID1A exhibit fewer dendritic branches and spines, and abnormal electrophysiological activity. Importantly, supplementation of acetate, an epigenetic metabolite, can ameliorate the morphological and electrophysiological deficits observed in mice with Arid1a haploinsufficiency, as well as in ARID1A-null human excitatory neurons. Mechanistically, transcriptomic and ChIP-seq analyses demonstrate that acetate supplementation can increase the levels of H3K27 acetylation at the promoters of key regulatory genes associated with neural development and synaptic transmission. Collectively, these findings support the essential roles of ARID1A in the excitatory neurons and cognition and suggest that acetate supplementation could be a potential therapeutic intervention for CSS.

Open article ↗



2021-05-19 | A partial ARID1B deletion in a female child with intractable epilepsy

Although epilepsy is a known complication in Coffin-Siris syndrome, its clinical symptoms and effective treatment methods have not been thoroughly investigated so far. Here, we present the case of a female with a 594-kb interstitial deletion at 6q25.3, involving partially ARID1B, with developmental delay, short stature, and intractable epilepsy. At 4 years of age, she developed epilepsy with clonic seizures in the right half of her body. Treatment with carbamazepine, levetiracetam, or topiramate was ineffective. The frequency of epileptic seizures gradually worsened. At the peak of her seizures, she had focal onset clonic seizures 3-4 times a month, and neck atonic seizures lasting for several seconds more than 10 times a day. After administration of sodium valproate, her epileptic seizures decreased to 0-1 times a year. In conclusion, gathering genetic information in Coffin-Siris syndrome allows improvement of epilepsy treatment and outcomes in these patients.

Open article ↗



cell therapies
2026-04-09 | Intranasal exosome therapy in Coffin-Siris syndrome: Clinical evaluation of three children.

Coffin-Siris Syndrome (CSS) is a rare neurodevelopmental condition most often caused by pathogenic variants in the ARID1B gene, a key component of the SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin-remodeling complex. Despite multidisciplinary interventions, functional improvement in CSS remains limited. Exosome-based therapeutics have recently gained attention for their potential neuroregenerative and neuroprotective properties. This case series included three children with genetically confirmed ARID1B-related CSS who received intranasal exosome therapy in addition to ongoing rehabilitation. Adaptive functioning was evaluated before and after treatment using the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3). Post-treatment assessments were performed 4-6 weeks after completion of the final intranasal exosome treatment cycle. Following the therapies, all patients demonstrated increases in the Adaptive Behavior Composite (ABC) score. The mean score increased from 83.0 pre-treatment to 90.7 post-treatment, corresponding to a mean improvement of 7.7 points (approximately +9%). Improvements were observed primarily in communication, daily living, and socialization domains, while motor-related changes were more modest yet clinically observable. No adverse events were observed during treatment. Given the small sample size, retrospective design, and concurrent rehabilitation therapies, these findings should be interpreted cautiously. These preliminary observations suggest that intranasal exosome therapy may represent a feasible and well-tolerated adjunctive approach to support adaptive functioning in children with CSS. Further controlled studies are warranted to confirm efficacy and elucidate the underlying mechanisms.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.